Clinical Trial Update: Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating monosialotetrahexosylganglioside for treatment of oxaliplatin-induced neurotoxicity in gastrointestinal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Oxaliplatin-induced Neurotoxicity

Drugs mentioned

• Monosialotetrahexosylganglioside (monosialotetrahexosylganglioside)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Neurotoxicity | Phase 3 | Status: COMPLETED